In the case of lung cancer, it is well known that EGFR-activating mutations can be used as a biomarker to stratify patients for EGFR TKI treatment as lung cancer harboring EGFR mutations is addicted to EGFR activation and thus sensitive to EGFR TKIs. Here, EGFR is linked to lung cancer.